Skip to main content
Top
Published in: Annals of Hematology 2/2014

01-02-2014 | Original Article

Protection of ovarian function by two distinct methods of ovarian shielding for young female patients who receive total body irradiation

Authors: Yoshinobu Kanda, Hidenori Wada, Ryoko Yamasaki, Koji Kawamura, Yuko Ishihara, Kana Sakamoto, Masahiro Ashizawa, Miki Sato, Tomohito Machishima, Kiriko Terasako-Saito, Shun-ichi Kimura, Hideki Nakasone, Misato Kikuchi, Rie Yamazaki, Junya Kanda, Shinichi Kako, Junji Nishida, Hidekazu Tsunoda, Yoshio Omori, Masanori Nakazawa, Osamu Tanaka

Published in: Annals of Hematology | Issue 2/2014

Login to get access

Abstract

To prevent ovarian dysfunction due to total body irradiation, we started ovarian shielding at our center (Saitama Medical Center, Jichi Medical University (SMC-JMU)) with a long source axis distance, which is different from the original method used at the University of Tokyo Hospital (UTH). We retrospectively analyzed the outcome of eight patients with a median age of 20.5 years from SMC-JMU and compared the results with the published data for eight patients with a median age of 22 years from UTH. The recovery of ovarian function was observed in five and six patients, respectively. The cumulative incidence of ovarian recovery, while treating relapse and death without ovarian recovery as competing risks, was 68.8 % at 2 years after transplantation in the total population, and there was no statistically significant difference between the two institutions (p = 0.85). Age and the history of previous chemotherapy did not affect the incidence of ovarian recovery. Two patients from each center had a relapse of leukemia. Overall, among the 11 patients who have survived without relapse, only one has not achieved ovarian recovery. In conclusion, ovarian shielding with both methods strongly protected ovarian function. However, we should continue to monitor the relapse rate among patients who undergo this procedure.
Literature
1.
go back to reference Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, Korthof E, Weis J, Levy V, Tichelli A (2003) Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101(9):3373–3385PubMedCrossRef Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, Korthof E, Weis J, Levy V, Tichelli A (2003) Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101(9):3373–3385PubMedCrossRef
2.
go back to reference Okuda S, Sato M, Terasako K, Kako S, Oshima K, Kanda Y (2009) Should busulfan-containing regimen be avoided for young female patients undergoing hematopoietic stem cell transplantation? Bone Marrow Transplant 43(3):261–262. doi:10.1038/bmt.2008.309 PubMedCrossRef Okuda S, Sato M, Terasako K, Kako S, Oshima K, Kanda Y (2009) Should busulfan-containing regimen be avoided for young female patients undergoing hematopoietic stem cell transplantation? Bone Marrow Transplant 43(3):261–262. doi:10.​1038/​bmt.​2008.​309 PubMedCrossRef
4.
go back to reference Kuwayama M, Vajta G, Kato O, Leibo SP (2005) Highly efficient vitrification method for cryopreservation of human oocytes. Reprod BioMed Online 11:300–308PubMedCrossRef Kuwayama M, Vajta G, Kato O, Leibo SP (2005) Highly efficient vitrification method for cryopreservation of human oocytes. Reprod BioMed Online 11:300–308PubMedCrossRef
5.
go back to reference Nagashima T, Muroi K, Kawano-Yamamoto C, Miyoshi T, Ohmine K, Toshima M, Miyazato A, Takatoku M, Nagai T, Mori M, Komatsu N, Ozawa K (2005) Autologous gamete cryopreservation before hemopoietic stem cell transplantation. Med Sci Monit 11(3):CR91–CR94PubMed Nagashima T, Muroi K, Kawano-Yamamoto C, Miyoshi T, Ohmine K, Toshima M, Miyazato A, Takatoku M, Nagai T, Mori M, Komatsu N, Ozawa K (2005) Autologous gamete cryopreservation before hemopoietic stem cell transplantation. Med Sci Monit 11(3):CR91–CR94PubMed
6.
go back to reference Courbiere B, Prebet T, Mozziconacci MJ, Metzler-Guillemain C, Saias-Magnan J, Gamerre M (2010) Tumor cell contamination in ovarian tissue cryopreserved before gonadotoxic treatment: should we systematically exclude ovarian autograft in a cancer survivor? Bone Marrow Transplant 45(7):1247–1248. doi:10.1038/bmt.2009.313 PubMedCrossRef Courbiere B, Prebet T, Mozziconacci MJ, Metzler-Guillemain C, Saias-Magnan J, Gamerre M (2010) Tumor cell contamination in ovarian tissue cryopreserved before gonadotoxic treatment: should we systematically exclude ovarian autograft in a cancer survivor? Bone Marrow Transplant 45(7):1247–1248. doi:10.​1038/​bmt.​2009.​313 PubMedCrossRef
7.
go back to reference Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K (2013) Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510. doi:10.1200/JCO.2013.49.2678 PubMedCrossRef Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K (2013) Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510. doi:10.​1200/​JCO.​2013.​49.​2678 PubMedCrossRef
8.
go back to reference Nakagawa K, Kanda Y, Yamashita H, Hosoi Y, Oshima K, Ohtomo K, Ban N, Yamakawa S, Nakagawa S, Chiba S (2006) Preservation of ovarian function by ovarian shielding when undergoing total body irradiation for hematopoietic stem cell transplantation: a report of two successful cases. Bone Marrow Transplant 37(6):583–587PubMedCrossRef Nakagawa K, Kanda Y, Yamashita H, Hosoi Y, Oshima K, Ohtomo K, Ban N, Yamakawa S, Nakagawa S, Chiba S (2006) Preservation of ovarian function by ovarian shielding when undergoing total body irradiation for hematopoietic stem cell transplantation: a report of two successful cases. Bone Marrow Transplant 37(6):583–587PubMedCrossRef
9.
go back to reference Nakagawa K, Kanda Y, Yamashita H, Nakagawa S, Sasano N, Ohtomo K, Oshima K, Kumano K, Ban N, Nannya Y, Kurokawa M, Chiba S (2008) Ovarian shielding allows ovarian recovery and normal birth in female hematopoietic SCT recipients undergoing TBI. Bone Marrow Transplant 42(10):697–699. doi:10.1038/bmt.2008.234 PubMedCrossRef Nakagawa K, Kanda Y, Yamashita H, Nakagawa S, Sasano N, Ohtomo K, Oshima K, Kumano K, Ban N, Nannya Y, Kurokawa M, Chiba S (2008) Ovarian shielding allows ovarian recovery and normal birth in female hematopoietic SCT recipients undergoing TBI. Bone Marrow Transplant 42(10):697–699. doi:10.​1038/​bmt.​2008.​234 PubMedCrossRef
10.
go back to reference Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef
11.
go back to reference Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZK' for medical statistics. Bone Marrow Transplant 48(3):452–458 Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZK' for medical statistics. Bone Marrow Transplant 48(3):452–458
12.
go back to reference Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, Chauncey TR, Storb R, Deeg HJ (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20(1):128–135. doi:10.1038/sj.leu.2404010 PubMedCrossRef Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, Chauncey TR, Storb R, Deeg HJ (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20(1):128–135. doi:10.​1038/​sj.​leu.​2404010 PubMedCrossRef
13.
go back to reference Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M (2008) Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 83(3):226–232. doi:10.1002/ajh.21087 PubMedCrossRef Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M (2008) Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 83(3):226–232. doi:10.​1002/​ajh.​21087 PubMedCrossRef
14.
go back to reference Kanda Y, Sakamoto K, Ashizawa M, Sato M, Terasako K, Kikuchi M, Kimura SI, Okuda S, Kako S, Oshima K (2011) Risks and benefits of ovarian shielding in female patients undergoing TBI: a decision analysis. Bone Marrow Transplant 46(8):1145–1147. doi:10.1038/bmt.2010.240 PubMedCrossRef Kanda Y, Sakamoto K, Ashizawa M, Sato M, Terasako K, Kikuchi M, Kimura SI, Okuda S, Kako S, Oshima K (2011) Risks and benefits of ovarian shielding in female patients undergoing TBI: a decision analysis. Bone Marrow Transplant 46(8):1145–1147. doi:10.​1038/​bmt.​2010.​240 PubMedCrossRef
Metadata
Title
Protection of ovarian function by two distinct methods of ovarian shielding for young female patients who receive total body irradiation
Authors
Yoshinobu Kanda
Hidenori Wada
Ryoko Yamasaki
Koji Kawamura
Yuko Ishihara
Kana Sakamoto
Masahiro Ashizawa
Miki Sato
Tomohito Machishima
Kiriko Terasako-Saito
Shun-ichi Kimura
Hideki Nakasone
Misato Kikuchi
Rie Yamazaki
Junya Kanda
Shinichi Kako
Junji Nishida
Hidekazu Tsunoda
Yoshio Omori
Masanori Nakazawa
Osamu Tanaka
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 2/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1852-8

Other articles of this Issue 2/2014

Annals of Hematology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine